Focal ablation technique for intermediate-risk prostate cancer continues to show safety May 9, 2021 The NanoTherm therapy system for focal ablation of intermediate-risk prostate cancer continued to show a tolerable safety profile in a recent analysis.Additional supportive data from stage 2a of a pivotal study of the NanoTherm therapy system for focal ablation of intermediate-risk prostate cancer confirm the initial findings showing that the treatment modality was safe and effective, according to MagForce AG who is responsible for developing the system.1Results were taken from a 10-patient cohort showing that only minimal treatment-related adverse effects and a tolerable safety profile were reported. Read the full article here. Source: Audrey Sternberg - Cancer Network About Prostate Cancer Prostate Cancer News Research Treatment Options More for you
The NanoTherm therapy system for focal ablation of intermediate-risk prostate cancer continued to show a tolerable safety profile in a recent analysis.Additional supportive data from stage 2a of a pivotal study of the NanoTherm therapy system for focal ablation of intermediate-risk prostate cancer confirm the initial findings showing that the treatment modality was safe and effective, according to MagForce AG who is responsible for developing the system.1Results were taken from a 10-patient cohort showing that only minimal treatment-related adverse effects and a tolerable safety profile were reported. Read the full article here. Source: Audrey Sternberg - Cancer Network
